{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:10:41Z","timestamp":1757700641689},"reference-count":16,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":10037,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1985,2]]},"abstract":"<jats:p>Fifty patients with mild essential (primary) hypertension entered a double\u2010blind, parallel\u2010group study with either nicardipine 30 mg three times daily or placebo, randomly assigned as monotherapy for 6 weeks. At the end of 6 weeks, the nicardipine\u2010treated group had a statistically significant reduction in mean supine systolic\/diastolic pressure of 21.2\/15.0 mm Hg (P less than 0.001) compared with the nonsignificant reduction of 0.7\/2.9 mm Hg in the placebo\u2010treated group. The difference in mean response between the nicardipine\u2010 and placebo\u2010 treated groups was significant (P less than 0.001). In the nicardipine\u2010 treated group, the reduction in mean standing systolic\/diastolic blood pressure, 17.9\/13.8 mm Hg, was significant (P less than 0.001), whereas in the placebo\u2010treated group the change was +3.0\/\u20101.5 mm Hg. The difference between the two treatment groups was significant (P less than 0.001). In both treatment groups, changes in pulse rate were minor, and there was no evidence of tachyphylaxis occurring with nicardipine. Adverse experiences were minor in all cases except for one patient with muscle pain during treatment with nicardipine. Patients who received nicardipine showed a mean increase of 52% in plasma renin activity (PRA) after 6 weeks (P less than 0.01). Initial basal or stimulated PRA did not correlate with blood pressure reduction on nicardipine. Nicardipine 30 mg three times daily is a well\u2010tolerated and effective antihypertensive agent.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1985.tb05153.x","type":"journal-article","created":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T22:07:55Z","timestamp":1343340475000},"source":"Crossref","is-referenced-by-count":31,"title":["Nicardipine hydrochloride in essential hypertension\u2010a controlled study."],"prefix":"10.1111","volume":"20","author":[{"given":"J.","family":"Asplund","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"387","article-title":"A fixed combination of metoprolol and hydrochlorothiazide in essential hypertension; a comparison between the individual drugs","volume":"29","author":"Asplund J.","year":"1981","journal-title":"Curr. Ther. Res."},{"key":"e_1_2_1_3_1","unstructured":"BalaSubramanian V.&Raftery E. B.(1981).The role of verapamil in chronic stable angina and hypertension.Scientific exhibit at the 30th Annual Scientific Session American College of Cardiology."},{"issue":"8","key":"e_1_2_1_4_1","doi-asserted-by":"crossref","first-page":"439S","DOI":"10.1042\/cs063439s","article-title":"Greater antihypertensive efficacy of the calcium channel inhibitor verapamil in older and low renin patients","volume":"63","author":"B\u00fchler F. R.","year":"1982","journal-title":"Clin. Sci."},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/22.2.250"},{"key":"e_1_2_1_6_1","first-page":"280","volume-title":"Calcium antagonism in cardiovascular therapy","author":"Gould B. A.","year":"1981"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-198306000-00014"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1974.00320180135012"},{"key":"e_1_2_1_9_1","first-page":"351","article-title":"The treatment of hypertension with verapamil","volume":"87","author":"Lewis G. R.","year":"1978","journal-title":"N.Z. med. J."},{"key":"e_1_2_1_10_1","doi-asserted-by":"crossref","first-page":"343S","DOI":"10.1042\/cs059343s","article-title":"State of the Art Review. Haemodynamics in essential hypertension","volume":"59","author":"Lund\u2010Johansen P.","year":"1980","journal-title":"Clin. Sci."},{"key":"e_1_2_1_11_1","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1001\/archinte.1981.00340040078021","article-title":"Multiclinic comparison of amiloride, hydrochlorothiazide, and hydrochlorothiazide plus amiloride in essential hypertension","volume":"141","author":"Multicentre Diuretic Co\u2010operative Study Group","year":"1981","journal-title":"Archs. intern. Med."},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00547413"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.59.5.1056"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00618511"},{"key":"e_1_2_1_15_1","first-page":"346","article-title":"Antihypertensive effect of nicardipine hydrochloride in essential hypertension","volume":"20","author":"Takabatake T.","year":"1982","journal-title":"Int. J. clin. Pharmac. Ther. Tox."},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198209000-00016"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1042\/cs0660233"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1985.tb05153.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1985.tb05153.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T23:35:08Z","timestamp":1697758508000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1985.tb05153.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,2]]},"references-count":16,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[1985,2]]}},"alternative-id":["10.1111\/j.1365-2125.1985.tb05153.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1985.tb05153.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,2]]}}}